Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand
Introduction: Efavirenz (EFV) is commonly used for first-line antiretroviral therapy in children and adolescents with HIV, but is associated with neuropsychiatric and metabolic side effects. Rilpivirine (RPV) is better tolerated, and switching from EFV to RPV in virologically suppressed adults has b...
Saved in:
Main Author: | Phongsamart W. |
---|---|
Other Authors: | Mahidol University |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/87438 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand
by: Wanatpreeya Phongsamart, et al.
Published: (2022) -
Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents
by: Watsamon Jantarabenjakul, et al.
Published: (2018) -
Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents
by: Watsamon Jantarabenjakul, et al.
Published: (2019) -
Safety and effectiveness of switching to abacavir/lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
by: Lim, Z. C., et al.
Published: (2021) -
Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
by: Lim, Z. C., et al.
Published: (2022)